We are live on ! Find out more
CMPX icon

Compass Therapeutics
CMPX

73 hedge funds and large institutions have $288M invested in Compass Therapeutics in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $267M → $288M (+$21.1M)

7.11% more ownership

Funds ownership: 64.41% → 71.52% (+7.1%)

1% more funds holding

Funds holding: 72 → 73 (+1)

8% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 24

6% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 18

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
73
Holders Change
+1
Holders Change %
+1.39%
% of All Funds
1.15%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
26
Increased
19
Reduced
18
Closed
24
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
BlackRock
New York
+$14.1M
2
B
Braidwell
Connecticut
+$8.5M
3
Blackstone Inc
Blackstone Inc
New York
+$4.33M
4
State Street
State Street
Massachusetts
+$4.22M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.9M

Top Sellers

1
FCMV
Foresite Capital Management V
California
-$6.77M
2
Millennium Management
Millennium Management
New York
-$2.56M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.38M
4
FAM
Fred Alger Management
New York
-$1.32M
5
Jane Street
Jane Street
New York
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
Marshall Wace
76
Marshall Wace
United Kingdom
– -$213K -65,177 Closed
Renaissance Technologies
77
Renaissance Technologies
New York
– -$171K -52,300 Closed
CSS
78
Cubist Systematic Strategies
Connecticut
– -$169K -51,576 Closed
Citadel Advisors
79
Citadel Advisors
Florida
– -$145K -44,460 Closed
WS
80
Wedbush Securities
California
– -$142K -43,444 Closed
6CM
81
683 Capital Management
New York
– -$124K -38,039 Closed
JF
82
Jump Financial
Illinois
– -$89.3K -27,310 Closed
BFM
83
Boothbay Fund Management
New York
– -$88.1K -26,945 Closed
Balyasny Asset Management
84
Balyasny Asset Management
Illinois
– -$87.7K -26,828 Closed
DC
85
Diametric Capital
Massachusetts
– -$85.8K -26,227 Closed
Verition Fund Management
86
Verition Fund Management
Connecticut
– -$75.4K -23,062 Closed
LIP
87
Lighthouse Investment Partners
Florida
– -$67.8K -20,723 Closed
ECM
88
ExodusPoint Capital Management
New York
– -$55K -16,840 Closed
Squarepoint
89
Squarepoint
New York
– -$53.2K -16,263 Closed
Two Sigma Investments
90
Two Sigma Investments
New York
– -$49.8K -15,222 Closed
PMEF
91
Point72 Middle East FZE
United Arab Emirates
– -$47.4K -14,497 Closed
SSA
92
Schonfeld Strategic Advisors
New York
– -$46.2K -14,127 Closed
JFG
93
Jefferies Financial Group
New York
– -$40.7K -12,434 Closed
TC
94
TwinBeech Capital
New York
– -$34.4K -10,506 Closed
Point72 Asset Management
95
Point72 Asset Management
Connecticut
– -$5K -1,528 Closed
QT
96
Quantbot Technologies
New York
– -$56 -17 Closed
ACM
97
Aquatic Capital Management
Illinois
– +$314 +100 New
1 2 3
4

CMPX Hedge Fund Activity: Q2 2023 in Review

73 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q2 2023, worth a combined $288M — up 7.9% from $267M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new CMPX positions and 24 closed out — a net gain of 2 holders — while 19 added to existing stakes and 18 trimmed.

The largest buyer was BlackRock, adding an estimated $14.1M. The largest seller was Foresite Capital Management V, cutting an estimated $6.77M.

  • 73 institutional investors held Compass Therapeutics (CMPX) as of Q2 2023, up from 72 in Q1 2023.
  • Funds reported $288M of Compass Therapeutics stock for Q2 2023, up 7.9% quarter-over-quarter.
  • 26 funds opened new Compass Therapeutics positions in Q2 2023 and 24 closed out, a net change of +2 holders.
  • The largest Compass Therapeutics buyer in Q2 2023 was BlackRock, an estimated $14.1M added.
  • The largest Compass Therapeutics seller in Q2 2023 was Foresite Capital Management V, an estimated $6.77M sold.

Based on aggregated 13F filings for Q2 2023.